91-105 of 949
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
CardiologyHypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Florian Rader, MD
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
CardiologySCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Joseph Rossano, MD
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
CardiologyHypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Joseph Rossano, MD
Heart Failure Hospitalization and Mortality in Cardiac Amyloidosis
Heart MattersHeart Failure Hospitalization and Mortality in Cardiac Amyloidosis
Frederick Ruberg, MD
Disease-Modifying Advances in ATTR-CM Management
Heart MattersDisease-Modifying Advances in ATTR-CM Management
- advertisement
Integrating CMR and Genetics to Improve ATTR-CM Diagnosis
AudioAbstractsIntegrating CMR and Genetics to Improve ATTR-CM Diagnosis
Ryan Quigley
Hidden HFpEF in Atrial Fibrillation: A Missed Diagnosis with Real Consequences
Heart MattersHidden HFpEF in Atrial Fibrillation: A Missed Diagnosis with Real Consequences
Plasma Biomarkers Associated with HF Hospitalization in Atrial Fibrillation
Heart MattersPlasma Biomarkers Associated with HF Hospitalization in Atrial Fibrillation
FAI and the Future of Cardiac Risk Stratification
Heart MattersFAI and the Future of Cardiac Risk Stratification
Redefining ATTR-CM Care in the Age of Targeted Therapy
On the Frontlines of ATTR-CMRedefining ATTR-CM Care in the Age of Targeted Therapy
Steve Jackson, PharmD
David Rind, MD, MSc
Tracking Disease Progression in ATTR-CM
On the Frontlines of ATTR-CMTracking Disease Progression in ATTR-CM
Ryan Quigley
Joban Vaishnav, MD
- advertisement
Understanding Vutrisiran’s Cardiac Effects in HELIOS-B
On the Frontlines of ATTR-CMUnderstanding Vutrisiran’s Cardiac Effects in HELIOS-B
Steve Jackson, PharmD
Karola Jering, MD
RNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
On the Frontlines of ATTR-CMRNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
Shelina Ramnarine, PhD
Chadi Alraies, MD, MPH, FACC
Can AI Transform How We Diagnose ATTR-CM?
On the Frontlines of ATTR-CMCan AI Transform How We Diagnose ATTR-CM?
Ryan Quigley
Frederick Ruberg, MD
